These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23237488)

  • 1. A liver-selective LXR inverse agonist that suppresses hepatic steatosis.
    Griffett K; Solt LA; El-Gendy Bel-D; Kamenecka TM; Burris TP
    ACS Chem Biol; 2013 Mar; 8(3):559-67. PubMed ID: 23237488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis.
    Griffett K; Welch RD; Flaveny CA; Kolar GR; Neuschwander-Tetri BA; Burris TP
    Mol Metab; 2015 Apr; 4(4):353-7. PubMed ID: 25830098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease.
    Griffett K; Burris TP
    Biochem Biophys Res Commun; 2016 Oct; 479(3):424-428. PubMed ID: 27680310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
    Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
    Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver.
    Sim WC; Park S; Lee KY; Je YT; Yin HQ; Choi YJ; Sung SH; Park SJ; Park HJ; Shin KJ; Lee BH
    Biochem Pharmacol; 2014 Aug; 90(4):414-24. PubMed ID: 24955981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease.
    Sengupta M; Griffett K; Flaveny CA; Burris TP
    ACS Pharmacol Transl Sci; 2018 Sep; 1(1):50-60. PubMed ID: 31696159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice.
    Sheng X; Wang M; Lu M; Xi B; Sheng H; Zang YQ
    Am J Physiol Endocrinol Metab; 2011 May; 300(5):E886-93. PubMed ID: 21364120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma.
    Na TY; Shin YK; Roh KJ; Kang SA; Hong I; Oh SJ; Seong JK; Park CK; Choi YL; Lee MO
    Hepatology; 2009 Apr; 49(4):1122-31. PubMed ID: 19105208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure activity relationship of the first class of LXR inverse agonists.
    Elgendy B; Griffett K; Hegazy L; Di Fruscia P; Sample K; Schoepke E; Kamenecka TM; Burris TP
    Bioorg Chem; 2022 Feb; 119():105540. PubMed ID: 34902646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design.
    Oosterveer MH; Grefhorst A; Groen AK; Kuipers F
    Prog Lipid Res; 2010 Oct; 49(4):343-52. PubMed ID: 20363253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor.
    Kim GH; Oh GS; Yoon J; Lee GG; Lee KU; Kim SW
    J Clin Invest; 2015 Jan; 125(1):183-93. PubMed ID: 25437875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The liver X receptor: a master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease.
    Ducheix S; Montagner A; Theodorou V; Ferrier L; Guillou H
    Biochem Pharmacol; 2013 Jul; 86(1):96-105. PubMed ID: 23542537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LXR{beta} is the dominant LXR subtype in skeletal muscle regulating lipogenesis and cholesterol efflux.
    Hessvik NP; Boekschoten MV; Baltzersen MA; Kersten S; Xu X; Andersén H; Rustan AC; Thoresen GH
    Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E602-13. PubMed ID: 19996385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid receptor-related orphan receptor α-induced activation of adenosine monophosphate-activated protein kinase results in attenuation of hepatic steatosis.
    Kim EJ; Yoon YS; Hong S; Son HY; Na TY; Lee MH; Kang HJ; Park J; Cho WJ; Kim SG; Koo SH; Park HG; Lee MO
    Hepatology; 2012 May; 55(5):1379-88. PubMed ID: 22183856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.
    Zhou J; Febbraio M; Wada T; Zhai Y; Kuruba R; He J; Lee JH; Khadem S; Ren S; Li S; Silverstein RL; Xie W
    Gastroenterology; 2008 Feb; 134(2):556-67. PubMed ID: 18242221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet.
    Uebanso T; Taketani Y; Yamamoto H; Amo K; Tanaka S; Arai H; Takei Y; Masuda M; Yamanaka-Okumura H; Takeda E
    J Nutr Biochem; 2012 Jul; 23(7):785-90. PubMed ID: 21889884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular biology and functional genomics of liver X receptors (LXR) in relationship to metabolic diseases.
    Faulds MH; Zhao C; Dahlman-Wright K
    Curr Opin Pharmacol; 2010 Dec; 10(6):692-7. PubMed ID: 20829110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver X receptors bridge hepatic lipid metabolism and inflammation.
    Liu Y; Qiu DK; Ma X
    J Dig Dis; 2012 Feb; 13(2):69-74. PubMed ID: 22257474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting liver X receptors in human health: deadlock or promising trail?
    Viennois E; Pommier AJ; Mouzat K; Oumeddour A; El Hajjaji FZ; Dufour J; Caira F; Volle DH; Baron S; Lobaccaro JM
    Expert Opin Ther Targets; 2011 Feb; 15(2):219-32. PubMed ID: 21204733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.